Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis

Journal of the Neurological Sciences

Volumn 303, Issue 1-2, 2011, Pages 109-113

  Healy, Brian C ^a,b,d   Engler, David ^c   Gholipour, Taha ^a   Weiner, Howard ^a   Bakshi, Rohit ^a   Chitnis, Tanuja ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM YOUNG UNIVERSITY   (United States)

^d Partners MS Center   (United States)

Author keywords

Disease modifying therapy; Disease progression; Longitudinal analysis; Multiple sclerosis; Statistical modeling

Indexed keywords

BETA INTERFERON; GLATIRAMER;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE DURATION; DISEASE MODIFYING THERAPY; DRUG EXPOSURE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE SCLEROSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SCORING SYSTEM; STATISTICAL MODEL; TREATMENT RESPONSE;

ADULT; AGE OF ONSET; AGED; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-BETA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SEX CHARACTERISTICS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952815849     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2010.12.024     Document Type: Article

References (18)

1. A. Compston McAlpine's multiple sclerosis 4th ed. 2005 Churchill Livingstone Elsevier Philadelphia
2. C. Confavreux, S. Vukusic, and P. Adeleine Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process Brain 126 Pt 4 2003 770 782 (Pubitemid 36372978)
3. B.G. Weinshenker, B. Bass, G.P. Rice, J. Noseworthy, W. Carriere, and J. Baskerville The natural history of multiple sclerosis: a geographically based study 2. Predictive value of the early clinical course Brain 112 Pt 6 1989 1419 1428 (Pubitemid 20024212)
4. B.G. Weinshenker, B. Bass, G.P. Rice, J. Noseworthy, W. Carriere, and J. Baskerville The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability Brain 112 Pt 1 1989 133 146 (Pubitemid 19056478)
5. C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine Relapses and progression of disability in multiple sclerosis N Engl J Med 343 20 2000 1430 1438
6. D.S. Goodin, E.M. Frohman, G.P. Garmany Jr., J. Halper, W.H. Likosky, and F.D. Lublin Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines Neurology 58 2 2002 169 178 (Pubitemid 34086933)
7. S.A. Gauthier, B.I. Glanz, M. Mandel, and H.L. Weiner A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study Autoimmun Rev 5 8 2006 532 536 (Pubitemid 44488756)
8. J.F. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 11 1983 1444 1452 (Pubitemid 14237132)
9. G.C. Ebers, L. Heigenhauser, M. Daumer, C. Lederer, and J.H. Noseworthy Disability as an outcome in MS clinical trials Neurology 71 9 2008 624 631
10. C. Liu, and L.D. Blumhardt Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts J Neurol Neurosurg Psychiatry 68 4 2000 450 457 (Pubitemid 30248744)
11. M.G. Brown, S. Kirby, C. Skedgel, J.D. Fisk, T.J. Murray, and V. Bhan How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 69 15 2007 1498 1507 (Pubitemid 47537856)
12. S.L. Zeger, and K.Y. Liang Longitudinal data analysis for discrete and continuous outcomes Biometrics 42 1 1986 121 130
13. M.A. Hernan, B. Brumback, and J.M. Robins Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men Epidemiology 11 5 2000 561 570 (Pubitemid 30660035)
14. V.A. Clark, R. Detels, B.R. Visscher, N.L. Valdiviezo, R.M. Malmgren, and J.P. Dudley Factors associated with a malignant or benign course of multiple sclerosis JAMA 248 7 1982 856 860 (Pubitemid 12041485)
15. D.H. Miller, R.W. Hornabrook, and G. Purdie The natural history of multiple sclerosis: a regional study with some longitudinal data J Neurol Neurosurg Psychiatry 55 5 1992 341 346
16. R. Detels, V.A. Clark, N.L. Valdiviezo, B.R. Visscher, R.M. Malmgren, and J.P. Dudley Factors associated with a rapid course of multiple sclerosis Arch Neurol 39 6 1982 337 341 (Pubitemid 12109203)
17. M.P. Amato, and G. Ponziani A prospective study on the prognosis of multiple sclerosis Neurol Sci 21 4 Suppl 2 2000 S831 S838
18. R.J.A. Little, and D.B. Rubin Statistical analysis with missing data 2nd ed. 2002 Wiley Hoboken, N.J.